Robinson, J. G., Farnier, M., Kastelein, J. J., Roth, E. M., Taskinen, M. R., Colhoun, H. M., … Cannon, C. P. (2016). Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis, 252, e231–e231. https://doi.org/10.1016/j.atherosclerosis.2016.07.219

Robinson, J. G., M. Farnier, J. J. Kastelein, E. M. Roth, M. R. Taskinen, H. M. Colhoun, A. Brunet, et al. “Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background.” Atherosclerosis 252 (September 2016): e231–e231. https://doi.org/10.1016/j.atherosclerosis.2016.07.219.

Robinson JG, Farnier M, Kastelein JJ, Roth EM, Taskinen MR, Colhoun HM, et al. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis. 2016 Sep;252:e231–e231.

Robinson, J. G., et al. “Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background.” Atherosclerosis, vol. 252, Elsevier BV, Sept. 2016, pp. e231–e231. Crossref, doi:10.1016/j.atherosclerosis.2016.07.219.

Robinson JG, Farnier M, Kastelein JJ, Roth EM, Taskinen MR, Colhoun HM, Brunet A, DiCioccio AT, Lecorps G, Pordy R, Baccara-Dinet MT, Cannon CP. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background. Atherosclerosis. Elsevier BV; 2016 Sep;252:e231–e231.